v3.22.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue:    
Grant and contract revenue $ 212,418 $ 538,645
Operating expenses:    
Research and development 3,933,347 3,406,248
General and administrative 3,776,623 4,767,645
Change in fair value of contingent consideration (21,000) 6,000
Total operating expenses 7,688,970 8,179,893
Loss from operations (7,476,552) (7,641,248)
Change in fair value of warrant liability 7,779 (8,702)
Interest income 120,702 195,165
Unrealized (loss) gain on available-for-sale securities (836,593) (164,513)
Other expense, net (5,134) (3,842)
Total non-operating income (loss) (713,246) 18,108
Net loss before income taxes (8,189,798) (7,623,140)
Net loss (8,189,798) (7,623,140)
Net loss - non-controlling interest (69,211) (90,962)
Net loss attributable to Heat Biologics, Inc. $ (8,120,587) $ (7,532,178)
Net loss per share, basic (in dollars per share) $ (0.32) $ (0.31)
Net loss per share, diluted (in dollars per share) $ (0.32) $ (0.31)
Weighted-average common shares outstanding, basic (in shares) 25,593,948 24,199,916
Weighted-average common shares outstanding, diluted (in shares) 25,593,948 24,199,916
Comprehensive loss:    
Net loss $ (8,189,798) $ (7,623,140)
Unrealized (loss) gain on foreign currency translation (55,269) 18,268
Total comprehensive loss (8,245,067) (7,604,872)
Comprehensive loss attributable to non-controlling interest (69,211) (90,962)
Comprehensive loss - Heat Biologics, Inc. $ (8,175,856) $ (7,513,910)

Source